TDS Pharm Co (XKRX:464280) ROCE % : 26.00% (As of Dec. 2023)

View and export this data going back to 2024. Start your Free Trial

What is TDS Pharm Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. TDS Pharm Co's annualized ROCE % for the quarter that ended in Dec. 2023 was 26.00%.

TDS Pharm Co ROCE % Historical Data

The historical data trend for TDS Pharm Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TDS Pharm Co ROCE % Chart

TDS Pharm Co Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

ROCE %

10.34

14.67

21.39

26.00

TDS Pharm Co Semi-Annual Data
	Dec20	Dec21	Dec22	Dec23
ROCE %	10.34	14.67	21.39	26.00

TDS Pharm Co ROCE % Calculation

TDS Pharm Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	5790.559	/	( ( (30468.621 - 9830.052)	+	(33970.008 - 10065.351) )	/ 2 )
	=	5790.559	/	( (20638.569	+	23904.657)	/ 2 )
	=	5790.559	/	22271.613
	=	26.00 %

TDS Pharm Co's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Dec. 2022 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Dec. 2022 )		(Q: Dec. 2023 )
	=	5790.559	/	( ( (30468.621 - 9830.052)	+	(33970.008 - 10065.351) )	/ 2 )
	=	5790.559	/	( ( 20638.569	+	23904.657 )	/ 2 )
	=	5790.559	/	22271.613
	=	26.00 %

(1) Note: The EBIT data used here is one times the annual (Dec. 2023) EBIT data.

TDS Pharm Co (XKRX:464280) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

TDS Pharm Co ROCE % Related Terms

Thank you for viewing the detailed overview of TDS Pharm Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

TDS Pharm Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » TDS Pharm Co Ltd (XKRX:464280) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

253 Pangyo-ro, Pangyo Inno Valley, Building C, Room 403, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13486

Website

https://www.tdspharm.com

TDS Pharm Co Ltd is engaged in the development and manufacturing of the Transdermal Drug Delivery System (TDDS), which is growing as a high-growth business sector in the field of drug delivery systems (DDS). The Transdermal Drug Delivery System (TDDS) is a drug delivery system that delivers drugs through the skin at a controlled speed. It has the advantages of increasing patient compliance with drugs, maximizing efficacy and effectiveness, such as minimizing side effects in the liver and digestive organs, controlling absorption rate, controlling discontinuation, controlling effective blood concentration, and enabling long-term continuous administration, and reducing burden compared to oral and injection drugs.

TDS Pharm Co Headlines

No Headlines